by GlyTherix | Sep 10, 2024
GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the manufacture of GlyTherix’s targeted radiotherapy antibody products for its US clinical...
by GlyTherix | Aug 29, 2024
GlyTherix is thrilled to be invited to speak at the AusBiotech 2024 National Conference. In a session titled “The rise of radiopharmaceuticals: How Australian biotech is at the forefront of this resurgence” GlyTherix CEO, Dr Brad Walsh will be presenting with other...
by GlyTherix | Jul 11, 2024
We are pleased to work with the Cyclowest team, Nat Lenzo and Thomas Tuchyna to bring new targeted radiotherapies to patients. Cyclowest started to produce Zirconium-89 with a plan to obtain TGA licensing for several Zr-89 products over the next 12 months. GlyTherix...
by GlyTherix | Jul 10, 2024
We are pleased to be attending the upcoming summit in Fremantle this coming Friday and Saturday. Looking forward to discussing GlyTherix Ltd’s targeted radiotherapy program which holds tremendous potential to enhance treatment efficacy while minimizing adverse...
by GlyTherix | May 1, 2024
Meet with targeted radiotherapy company GlyTherix Ltd in Boston and New York. Next week Brad Walsh, CEO and David Burdis, CFO will be joining with their advisors Atoll Financial Group for a roadshow in Boston Monday May 6 and Tuesday May 7 followed by New York May 8...
by GlyTherix | Apr 3, 2024
Sydney (Australia) – April 3, 2024. GlyTherix Ltd (GlyTherix) an Australian immuno-oncology company specialising in developing targeted radiotherapies for solid tumors today announces that Dr Colin Hayward has joined GlyTherix’s Clinical Advisory Board. Based in North...
